Suppr超能文献

游离轻链:多发性骨髓瘤患者早期独立的反应和进展预测因子。

Involved free light chain: an early independent predictor of response and progression in multiple myeloma.

机构信息

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.

出版信息

Leuk Lymphoma. 2021 Sep;62(9):2227-2234. doi: 10.1080/10428194.2021.1907370. Epub 2021 Apr 2.

Abstract

Serum and urine protein electrophoresis (sPEP/uPEP) are the standard methods for monitoring of multiple myeloma (MM). However, a method of detection with shorter half-life, such as serum-free light chain (FLC), could detect the response or progression earlier. In total, 450 MM patients were assessed in first, second, and third line. Response and progression were classified according to International myeloma working group guidelines. The overall median time to partial response or better was detectable significantly earlier with involved free light chain (iFLC) 1.94 months (IQR: 1.61-2.23) compared to sPEP 5.39 months (IQR: 3.88-7.00). In first line, iFLC detected progression earlier compared to sPEP, particularly in patients with progression more than 18 months after best response. In conclusion, a response observed by iFLC occurs at least a median of 3 months before response is detected by sPEP/uPEP.

摘要

血清和尿液蛋白电泳(sPEP/uPEP)是监测多发性骨髓瘤(MM)的标准方法。然而,半衰期更短的检测方法,如血清游离轻链(FLC),可以更早地检测到反应或进展。总共评估了 450 例一线、二线和三线 MM 患者。根据国际骨髓瘤工作组指南对反应和进展进行分类。与 sPEP 相比,受累游离轻链(iFLC)可更早检测到部分缓解或更好的总体中位时间为 1.94 个月(IQR:1.61-2.23),而 sPEP 为 5.39 个月(IQR:3.88-7.00)。在一线治疗中,iFLC 比 sPEP 更早检测到进展,尤其是在最佳反应后 18 个月以上进展的患者中。总之,与 sPEP/uPEP 相比,iFLC 检测到的反应至少早 3 个月。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验